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he Janus Face
f Nicotinic Angiogenesis*
ngelo Avogaro, MD, PHD,
ian Paolo Fadini, MD
adova, Italy
n 1559, Jean Nicot, a French ambassador in Lisbon, sailed
o Portugal to negotiate the marriage of Princess Marguerite
e Valois to King Sebastian of Portugal. When he returned,
e brought tobacco plants which had an immediate success,
nd was called nicotine: the term later came to refer only to
he active ingredient of the plant, which was identified as an
lkaloid. Nicotine is a major component of the particulate
hase of cigarette smoke, and it is also the contributing
gent of tobacco dependency. Its metabolites are highly
arcinogenic (1) as shown by several prospective studies.
oday, the tobacco epidemic kills more than 4 million
eople around the world annually and projected estimates
re dim: 10 million deaths a year worldwide by the year
015. Besides cancer, tobacco smoking strongly predisposes
he individual to clinical atherosclerotic syndromes. Smok-
ng impairs endothelium-dependent vasodilation, increases
eukocyte count and inflammatory markers, enhances the
ocal recruitment of leukocytes, and worsens lipid profile (2).
See page 2553
t appears that everything went wrong with Nicot’s decision.
owever, not tobacco smoking but nicotine itself has the
otential to be a valuable pharmaceutical agent: it specifi-
ally binds to the cholinergic site on cationic ion channels
eceptors (nAChR) in many tissues, including the endothe-
ium. This action has been shown to confer some protection
gainst Parkinson’s disease, Alzheimer’s disease, ulcerative
olitis, and sleep apnea (3). Surprisingly, some novel and
ositive effects of nicotine paradoxically involve the cardio-
ascular system. It has been shown that nicotine stimulates
ndothelial-cell proliferation via nAChR (4) and increases
xpression of endothelial nitric-oxide synthase (5). In 2001,
eeschen et al. (6) found that nicotine reduces apoptosis
nd increases proliferation of endothelial cells; expands
apillary networks; and enhances the angiogenic response to
nflammation, ischemia, atherosclerosis, and neoplasia.
hey also demonstrated that these proangiogenic effects are
ediated by non-neuronal nAChR (6) and subsequently
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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anofi-Aventis, Merck Sharp & Dohme, and AstraZeneca.howed that the cholinergic angiogenic pathways are depen-
ent on vascular endothelial growth factor (VEGF) and the
hosphatidylinositol 3-kinase and mitogen-activated pro-
ein kinase pathways (7). This evidence suggested that
icotine may even have healing properties in the cardiovas-
ular system revealing possible therapeutic implications. In
his issue of the Journal, a new important paper by Heeschen
t al. (8) demonstrates that endothelial progenitor cells
EPCs) participate in nicotine-mediated angiogenesis. En-
othelial progenitor cells are marrow-derived cells involved
n post-natal vasculogenesis and maintenance of endothelial
omeostasis. Reduction of the EPC pool is associated with
therosclerotic diseases (9), and the amount of EPCs in
eripheral blood reflects cardiovascular health and predicts
uture events (10,11). The authors show that systemic
icotine administration stimulates angiogenesis after femo-
al artery ligation with concomitant increase in plasma levels
f VEGF and c-kit ligand, which sustained bone marrow
obilization of CD34Flk-1 EPCs. Using parabiotic
ouse pairs, they show that EPC incorporation into the
ascent vasculature is potently enhanced in nicotine-treated
nimals versus controls. The parabiosis model represents an
deal assay to track the fate of EPCs in vivo, because it
xplores entirely endogenous processes and avoids biases of
one marrow transplantation. This study convincingly dem-
nstrates that ischemia-induced angiogenesis stimulated by
icotine is mediated by EPC mobilization and recruitment;
t also provides mechanistic insights showing that in vitro
xposure to nicotine stimulates EPC growth and transmi-
ration, confirming previous observations on EPCs from
ealthy individuals (12).
However, there remain unanswered questions about the
ffects of nicotine on EPCs that will need further consid-
ration. First, the authors show that systemic is more
ffective than local nicotine administration in stimulating
schemic angiogenesis. Nonetheless, local nicotine itself
romoted angiogenesis without reaching the systemic cir-
ulation. It is conceivable that nicotine locally induces
ngiogenic factors, which, in turn, stimulate vessel growth
y activation of resident endothelial cells; alternatively, the
ecruitment of circulating EPCs cannot be excluded. Un-
ortunately, we do not know whether EPC mobilization
akes place also after local nicotine injection.
Second, an important observation is that nicotine did not
timulateEPCmobilization in the absence of acute ischemia.One
ogical explanation is that tissue nAChR undergoes hypoxic
p-regulation during ischemia, and its subsequent activation by
icotine promotes the release of one or more mobilizing agents,
uch as VEGF or stem-cell-derived factor-1, both of which are
egulated by hypoxia-sensing systems. Indeed, the authors have
reviously demonstrated that nicotine induces the expression of
EGF (7). Therefore, we should note that, to stimulate angio-
enesis, the nicotinic pathwaywill necessitate the presence of acute
schemia, possibly limiting its therapeutic effects on chronic stable
therosclerotic diseases.
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Editorial Comment December 19, 2006:2561–3Third, surprisingly, in vitro nicotine stimulated EPC
rowth at a 107 to 106 molar concentration, which is very
lose to the concentrations at which nicotine induces cytotox-
city (106 mol), whereas inhibition of hematopoiesis has been
hown with higher concentrations (105 to 104 mol) (13).
Notwithstanding these limitations, the findings reported by
eeschen et al. (8) represent an important preliminary proposal to
timulate vasculogenesis in a clinical setting of ischemia. A
ractical consequence of this has been shown: nicotine was able to
ccelerate wound healing in control and genetically diabetic mice
14). From a clinical point of view, the use of nicotine can be
ypothesized in those conditions associated with decreased num-
er of EPCs. A case for this is diabetes mellitus, which is
haracterized by a decreased number and function ofEPCs (9,15).
nother potentially beneficial effect of nicotine is its ability to
nduce VEGF expression: this may be relevant because it has been
uggested that progressive down-regulation of VEGF is a pivotal
vent in the development of diabetic cardiomyopathy (16).
Obviously, the therapeutic translation of nicotine use in
he clinical setting raises relevant questions. The major
obacco-related diseases (cancer, atherosclerosis, and macu-
ar degeneration) have a proangiogenetic stage, which might
e mediated by nicotine through EPC mobilization and
ecruitment. Indeed, EPCs may be involved also in harmful
ngiogenesis, such as in cancer growth (17), plaque neovas-
ularization (18), and proliferative retinopathy (19). How-
ver, besides special conditions in which smoking may
ncrease EPCs (20,21), we must recognize that chronic
mokers themselves have a profound EPC impairment and
eduction, and that smoking cessation increases EPCs
ndependently from the use of nicotine patches (22,23).
herefore, we are compelled to keep the effects of nicotine
otally distinct from those of tobacco smoking. Nonetheless,
ith nicotine and EPCs, we are facing an angiogenic
aradox. Let us imagine designing a trial to test a system-
cally administered nAChR agonist for diabetic ischemic
oot ulcers; necessarily, we will be puzzled by the potential
armful effects of improper cholinergic angiogenesis on
therosclerotic plaque growth and retinal neovascularization
n those patients. Therefore, local nicotine administration
ay be preferred to avoid side effects at distant sites.
nother possible limitation to nicotine use applied to the
omplex human phenotype: the PI-3K/Akt pathway, criti-
al for both EPC mobilization and cholinergic angiogenesis
7,24), is dysfunctional in many conditions of increased
ardiovascular risk, including diabetes (25). Furthermore, if
icotinic angiogenesis requires EPCs, the severe impair-
ent of the endogenous EPC pool in diabetes and other
onditions may limit significantly the actual therapeutic
otentialities of nicotinic agonists in the clinical setting. Fi-
ally, we have recently shown alterations in hypoxia-sensing
ystems that not only prevent EPC mobilization in diabetes
26) but they may also inhibit nicotinic angiogenesis.
In conclusion, we are learning more about extraordinary
avorable actions of nicotine, but further efforts are needed
o unravel the implications of nicotinic angiogenesis inelation to EPC biology, before its clinical use. Where?
systemic vs. local), when? (patient selection), and how
uch? (the minimal efficacious dose) remain open questions.
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ipartimento di Medicina Clinica e Sperimentale, Malattie del
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